Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice

Clinical and Experimental Immunology

Volumn 137, Issue 2, 2004, Pages 263-271

  Kannan, Y ^a,b   Tokunaga, M ^a   Moriyama, M ^a   Kinoshita, H ^a   Nakamura, Y ^a  

^a Osaka Prefecture University   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

IL 1 ; Multiple low dose streptozotocin; Neutrophil infiltration; Phagocytosis; TNF ; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INTERLEUKIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; PIOGLITAZONE; ROSIGLITAZONE; SUPEROXIDE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HYPERGLYCEMIA; INFLAMMATORY INFILTRATE; LEUKOCYTE FUNCTION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM EXUDATE; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; ASCITIC FLUID; BLOOD GLUCOSE; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CHROMANS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; NEUTROPHIL INFILTRATION; NEUTROPHILS; PHAGOCYTOSIS; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE; THIAZOLIDINEDIONES; ZYMOSAN;

EID: 3543042569     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02532.x     Document Type: Article

References (52)

1. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982; 72:439-50.
2. Fahey TJ III, Sadaty A, Jones WG II, Barber A, Smoller B, Shires GT. Diabetes impairs the late inflammatory response to wound healing. J Surg Res 1991; 50:308-13.
3. Davidson NJ, Sowden JM, Fletcher J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins. J Clin Pathol 1984; 37:783-6.
4. -) production by polymorphonuclear neutrophils from patients with diabetes mellitus. Folia Haematol Int Mag Klin Morph Blutforsch 1985; 112:658-68.
5. Naghibi M, Smith RP, Baltch AL et al. The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Res Clin Pract 1987; 4:27-35.
6. Pereira MA, Sannomiya P, Leme JG. Inhibition of leukocyte chemotaxis by factor in alloxan-induced diabetic rat plasma. Diabetes 1987; 36:1307-14.
7. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15:256-60.
8. Serlenga E, Garofalo AR, De Pergola G, Ventura MT, Tortorella C, Antonaci S. Polymorphonuclear cell-mediated phagocytosis and superoxide anion release in insulin-dependent diabetes mellitus. Cytobios 1993; 74:189-95.
9. 1 level in diabetic patients. Diabetes Res Clin Pract 1993; 21:109-14.
10. Abu el-Asrar AM, Soliman RT, al-Amro SA, al-Shammary FJ. Production of superoxide anion by polymorphonuclear leukocytes from diabetic patients with or without diabetic retinopathy. Doc Ophthalmol 1996; 91:243-54.
11. Zozulinska DA, Wierusz-Wysocka B, Wysocki H, Majchrzak AE, Wykretowicz A. The influence of insulin-dependent diabetes mellitus (IDDM) duration on superoxide anion and hydrogen peroxide production by polymorphonuclear neutrophils. Diabetes Res Clin Pract 1996; 33:139-44.
12. Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001; 73:259-67.
13. Barouch FC, Miyamoto K, Allport JR et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000; 41:1153-8.
14. Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, McDonagh PF. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complications 2000; 14:96-107.
15. Esmann V. The diabetic leukocyte. Enzyme 1972; 13:32-55.
16. Tan AS, Ahmed N, Berridge MV. Acute regulation of glucose transport after activation of human peripheral blood neutrophils by phorbol myristate acetate, fMLP, and granulocyte-macrophage colony-stimulating factor. Blood 1998; 91:649-55.
17. Tebbs SE, Lumbwe CM, Tesfaye S, Gonzalez AM, Wilson RM. The influence of aldose reductase on the oxidative burst in diabetic neutrophils. Diabetes Res Clin Pract 1992; 15:121-9.
18. Sato N, Kashima K, Uehara Y, Ohtani K, Shimizu H, Mori M. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care 1997; 20:995-8.
19. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990; 39:271-5.
20. Sengoelge G, Fodinger M, Skoupy S et al. Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modifled fibronectin. Kidney Int 1998; 54:1637-51.
21. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000; 67:2405-16.
22. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34:217-24.
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-6.
24. Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278:704-11.
25. Aljada A, Ghanim H, Friedman J, Garg R, Mohanty P, Dandona P. Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects. J Clin Endocrinol Metab 2001; 86:3130-3.
26. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-6.
27. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19:2094-104.
28. Ikeda U, Shimpo M, Murakami Y, Shimada K. Peroxisome proliferator- activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension 2000; 35:1232-6.
29. Chen NG, Han X. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochem Biophys Res Commun 2001; 282:717-22.
30. Greene ME, Blumberg B, McBride OW et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4:281-99.
31. Inoue I, Katayama S, Takahashi K et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997; 235:113-6.
32. Garg R, Kumbkarni Y, Aljada A et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000; 36:430-5.
33. Yamashita M, Kushihara M, Hirasawa N et al. Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. Br J Pharmacol 2000; 129:367-73.
34. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF Jr. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci USA 1977; 74:2485-9.
35. Herold KC, Vezys V, Sun Q et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996; 156:3521-7.
36. Ogawa J, Takahashi S, Fujiwara T et al. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 1999; 65:1287-96.
37. Kiang SW, Kuan JW, Kuan SS, Guilbault GG. Measurement of glucose in plasma, with use of immobilized glucose oxidase and peroxidase. Clin Chem 1976; 22:1378-82.
38. Kannan Y, Ushio H, Koyama H et al. 2.5S nerve growth factor enhances survival, phagocytosis, and superoxide production of murine neutrophils. Blood 1991; 77:1320-5.
39. Mizuno T, Kannan Y, Tokunaga M et al. Role of hypothermia induced by tumor necrosis factor on apoptosis and function of inflammatory neutrophils in mice. Am J Physiol Regul Integr Comp Physiol 2000; 278:R157-65.
40. Valerius NH. Chemotaxis, spreanding and oxidative metabolism of neutrophils: influence of albumin in vitro. Acta Pathol Microbiol Immunol Scand [C] 1983; 91:43-9.
41. Czop JK, Puglisi AV, Miorandi DZ, Austen KF. Perturbation of betaglucan receptors on human neutrophils initiates phagocytosis and leukotriene B4 production. J Immunol 1988; 141:3170-6.
42. Getting SJ, Flower RJ, Perretti M. Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Br J Pharmacol 1997; 120:1075-82.
43. Djaldetti M, Salman H, Bergman M, Djaldetti R, Bessler H. Phagocytosis - the mighty weapon of the silent warriors. Microsc Res Tech 2002; 57:421-31.
44. Ribeiro RA, Vale ML, Thomazzi SM et al. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 2000; 387:111-8.
45. Perretti M, Solito E, Parente L. Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. Agents Actions 1992; 35:71-8.
46. Torok K, Nemeth K, Erdo F, Aranyi P, Szekely JI. Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Inflamm Res 1995; 44:248-52.
47. Fantuzzi G, Sacco S, Ghezzi P, Dinarello CA. Physiological and cytokine responses in IL-1 beta-deficient mice after zymosan-induced inflammation. Am J Physiol 1997; 273:R400-6.
48. Utsunomiya I, Ito M, Oh-ishi S. Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo. Cytokine 1998; 10:956-63.
49. Doxey DL, Nares S, Park B, Trieu C, Cutler CW, Iacopino AM. Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. Life Sci 1998; 63:1127-36.
50. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000; 49:1451-8.
51. Rao KM, Hatchell DL, Cohen HJ, De La Paz MA. Alterations in stimulus-induced integrin expression in peripheral blood neutrophils of patients with diabetic retinopathy. Am J Med Sci 1997; 313:131-7.
52. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147:642-53.